<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390780</url>
  </required_header>
  <id_info>
    <org_study_id>BA/2004/01/04</org_study_id>
    <nct_id>NCT00390780</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients</brief_title>
  <official_title>A Comparative Randomized, Double-blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onxeo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Onxeo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg
      (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days
      of treatment (at the test of cure visit, at Day 17-19).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale</measure>
    <time_frame>17 to 22 days</time_frame>
    <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure at Day 7 (Using Murray Scoring Scale)</measure>
    <time_frame>7 days</time_frame>
    <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)</measure>
    <time_frame>17 to 22 days</time_frame>
    <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success at Day 7 (Using Murray Scoring Scale)</measure>
    <time_frame>7 days</time_frame>
    <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response at Test of Cure Visit (Days 17-22) Using Murray Scoring Scale</measure>
    <time_frame>17 to 22 days</time_frame>
    <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Partial response is having decrease in Murray extent of oral lesions score by at least 1 level and a stable Murray symptoms score, with partial symptom response defined as having a decrease in the Murray symptoms (soreness/burning) score by at least 1 level and a stable Murray extent of oral lesions score, and partial clinical/symptom response defined as decrease in Murray extent of oral lesions score by at least 1 level and a decrease in the Murray symptoms (soreness/burning) score by at least 1 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Cure at the Test of Cure Visit (Day 17-22)</measure>
    <time_frame>17 to 22 days</time_frame>
    <description>Mycological cure was defined as a patient who had &quot;no yeast isolated&quot; when oral specimens were cultured for fungi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse at the Late Post-Therapy Visit (Day 35-38)</measure>
    <time_frame>35 to 38 days</time_frame>
    <description>&quot;Number of patients&quot; represents the number of participants who completed visit 6 (the late post-therapy visit on Days 35-38) and had been a clinical success at test-of-cure visit (visit 5). For this subset of participants, relapse was defined as a patient who responded to treatment by clinical cure or improvement (i.e., &quot;clinical success&quot;) on Days 17-22 at the test-of-cure visit (visit 5) and subsequently had an increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit on Days 35-38 (visit 6). No relapse indicates participants who were considered a &quot;clinical success&quot; at visit 5 and did not have a subsequent increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit (visit 6). The remaining number of participants in the Intent-to-Treat population who did not meet the criteria for relapse assessment at visit 6 is listed under &quot;Not Analyzed-ITT&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Discomfort Using Visual Analog Scale (VAS)</measure>
    <time_frame>14 days</time_frame>
    <description>Visual analog scale was used by the patient in the patient diary. The scale ranged from 0 (no oral discomfort) to 10 (maximum oral discomfort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General and Local Tolerability and Oral Discomfort</measure>
    <time_frame>14 days</time_frame>
    <description>Overall local adverse reactions, including gingival inflammation, gum pain, alterations in taste of food when eating, alterations in taste when not eating, and dry mouth. Visit 4 occurred on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Adhesion of Miconazole Lauriad 50 mg Mucoadhesive Buccal Tablet</measure>
    <time_frame>14 days</time_frame>
    <description>The mean durations of adhesion from initiation of treatment to Day 14 of miconazole Lauriad 50 mg mucoadhesive buccal tablet (or, in the case of the Clotrimazole troches treatment arm, the placebo mucoadhesive buccal tablet) were rounded to the nearest hour</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Exposure of Miconazole Lauriad 50 mg Bioadhesive Buccal Tablet</measure>
    <time_frame>7 days</time_frame>
    <description>Number of patients with detectable plasma concentration at Visit 3 (day 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Susceptibility of Candida Species by Microdilution Test</measure>
    <time_frame>Initiation of treatment to Day 17 to 22</time_frame>
    <description>minimum inhibitory concentration (MIC) in nonresponders at test-of-cure visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Compliance</measure>
    <time_frame>Initiation of treatment to Day 14</time_frame>
    <description>Number of patients who were 100% compliant with the treatment regimen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">578</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Clotrimazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>miconazole Lauriad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>miconazole Lauriad</intervention_name>
    <description>50 mg buccal tablet once a day for 14 days</description>
    <arm_group_label>miconazole Lauriad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>10mg troches administered Five Times a Day for 14 days</description>
    <arm_group_label>Clotrimazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical picture of oropharyngeal candidiasis

          -  Confirmation of oropharyngeal candidiasis by candida culture positive

          -  HIV-positive patients

          -  Patients 18 years of age

        Exclusion Criteria:

          -  Patients with signs or symptoms of systemic candidiasis

          -  Patients with signs or symptoms of esophagitis

          -  Pregnant or breast-feeding women

          -  Patients who have taken systemic antifungals within the past 30 days

          -  Patients who have taken local antifungals within the past 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama, Department of diagnostic Sciences School of Dentistry</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-00007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.A. Gay &amp; Lesbian center, Health &amp; Mental, health services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay AIDS Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1401 Noth Palm Canyon</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut, School of dental medicine</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryan White Title III Clinic</name>
      <address>
        <city>Labelle</city>
        <state>Florida</state>
        <zip>33935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Medical Services</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of oral medicine and diagnostic sciences UIC college of dentistry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-7213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Plus Clinic, University of Maryland Dental school</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital and Wayne State University, Division of infectious diseases</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Research Initiative of America</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department Diagnostics Sciences, UNC</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University, Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma, College of medicine</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital Clinical Research Department of Medicine</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roger Williams Medical Center</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bering Omega Dental Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical Center, Center for comprehensive care of immune deficiency</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Infectious Disease Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Center British Columbia Centre for excellence in HIV/AIDS</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>GG441-820</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Health Services</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institutes immunodeficiency clinic</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2x2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <results_first_submitted>September 7, 2012</results_first_submitted>
  <results_first_submitted_qc>July 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 29, 2013</results_first_posted>
  <last_update_submitted>September 5, 2013</last_update_submitted>
  <last_update_submitted_qc>September 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Miconazole Lauriad</keyword>
  <keyword>Oropharyngeal candidiasis</keyword>
  <keyword>HIV patients</keyword>
  <keyword>Mycology</keyword>
  <keyword>Clinical picture of Oropharyngeal candidiasis</keyword>
  <keyword>Candida culture positive</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from 25 July 06 to 27 December 07 A total of 30 clinical sites (private practice and hospitals) in US, Canada and South Africa screened patients for this study, and 28 sites randomized patients</recruitment_details>
      <pre_assignment_details>There were no significant events or approaches following participant enrollment and prior to group assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Miconazole Lauriad Buccal Tablet</title>
          <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Clotrimazole Troches</title>
          <description>Clotrimazole troches, 10 mg, 5 times per day, for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment</title>
              <participants_list>
                <participants group_id="P1" count="290">One patient randomized to miconazole lost study drug, never started treatment, and was discontinued.</participants>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not completed</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion criteria not satisfied</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to follow up and other reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision, SAE, other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE, death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Miconazole Lauriad Buccal Tablet</title>
          <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Clotrimazole Troches</title>
          <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="290"/>
            <count group_id="B2" value="287"/>
            <count group_id="B3" value="577"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.5" spread="9.7" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B2" value="36.5" spread="9.1" lower_limit="18" upper_limit="72"/>
                    <measurement group_id="B3" value="37.0" spread="9.4" lower_limit="18" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale</title>
        <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
        <time_frame>17 to 22 days</time_frame>
        <population>Intent-to-Treat (ITT, all randomized patients who took at least 1 dose of study medication)
Per Protocol (PP, all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale</title>
          <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
          <population>Intent-to-Treat (ITT, all randomized patients who took at least 1 dose of study medication)
Per Protocol (PP, all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Cure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses for ITT and PP populations:
H0: clinical cure rate for miconazole Lauriad minus clinical cure rate for clotrimazole troches is less than or equal to -0.15 H1: clinical cure rate for miconazole Lauriad minus clinical cure rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Expected cure rate: 70% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>&gt;0.025</p_value>
            <p_value_desc>Significance level was &lt;0.025</p_value_desc>
            <method>one-sided test</method>
            <param_type>comparison of proportion clinical cure</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure at Day 7 (Using Murray Scoring Scale)</title>
        <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
        <time_frame>7 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure at Day 7 (Using Murray Scoring Scale)</title>
          <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Cure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for ITT and PP populations:
H0: clinical cure rate for miconazole Lauriad minus clinical cure rate for clotrimazole troches is less than or equal to -0.15 H1: clinical cure rate for miconazole Lauriad minus clinical cure rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Expected cure rate: 70% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>&gt;0.025</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>one-sided noninferiority test</method>
            <param_type>comparison of proportion clinical cure</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)</title>
        <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
        <time_frame>17 to 22 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success at Test-of-cure Visit (Day 17-22) (Using Murray Scoring Scale)</title>
          <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Success-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for ITT population:
H0: clinical success rate for miconazole Lauriad minus clinical success rate for clotrimazole troches is less than or equal to -0.15 H1: clinical success rate for miconazole Lauriad minus clinical success rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.0974</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>compare proportion of clinical success</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for PP population:
H0: clinical success rate for miconazole Lauriad minus clinical success rate for clotrimazole troches is less than or equal to -0.15 H1: clinical success rate for miconazole Lauriad minus clinical success rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.1115</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Compare proportion of clinical success</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success at Day 7 (Using Murray Scoring Scale)</title>
        <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
        <time_frame>7 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success at Day 7 (Using Murray Scoring Scale)</title>
          <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Clinical cure was defined as a complete resolution of signs and symptoms (extent of oral lesions score = 0, symptoms score = 0). Clinical improvement was defined as having no visible lesion (extent of lesions score = 0) and minimal symptoms (soreness/burning score &lt;2). Clinical failure was defined as any patient who failed to be clinically cured by the treatment.</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Success-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Failure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for ITT population:
H0: clinical success rate for miconazole Lauriad minus clinical success rate for clotrimazole troches is less than or equal to -0.15 H1: clinical success rate for miconazole Lauriad minus clinical success rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.8787</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>compare proportion of clinical success</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for PP population:
H0: clinical success rate for miconazole Lauriad minus clinical success rate for clotrimazole troches is less than or equal to -0.15 H1: clinical success rate for miconazole Lauriad minus clinical success rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.7969</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>compare proportion of clinical success</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Partial Response at Test of Cure Visit (Days 17-22) Using Murray Scoring Scale</title>
        <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Partial response is having decrease in Murray extent of oral lesions score by at least 1 level and a stable Murray symptoms score, with partial symptom response defined as having a decrease in the Murray symptoms (soreness/burning) score by at least 1 level and a stable Murray extent of oral lesions score, and partial clinical/symptom response defined as decrease in Murray extent of oral lesions score by at least 1 level and a decrease in the Murray symptoms (soreness/burning) score by at least 1 level</description>
        <time_frame>17 to 22 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Response at Test of Cure Visit (Days 17-22) Using Murray Scoring Scale</title>
          <description>Murray scoring scale range: extent of oral lesions (signs) 0 (none) to 3 (extensive or confluent), ordinal; symptoms (soreness/burning) 0 (absent) to 3 (severe), ordinal. Clinical success was defined as clinical cure or clinical improvement. Partial response is having decrease in Murray extent of oral lesions score by at least 1 level and a stable Murray symptoms score, with partial symptom response defined as having a decrease in the Murray symptoms (soreness/burning) score by at least 1 level and a stable Murray extent of oral lesions score, and partial clinical/symptom response defined as decrease in Murray extent of oral lesions score by at least 1 level and a decrease in the Murray symptoms (soreness/burning) score by at least 1 level</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial response-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for ITT population:
H0: partial response rate for miconazole Lauriad minus partial response rate for clotrimazole troches is less than or equal to -0.15 H1: partial response rate for miconazole Lauriad minus partial response rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.8820</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>compare proportion of partial response</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for PP population:
H0: partial response rate for miconazole Lauriad minus partial response rate for clotrimazole troches is less than or equal to -0.15 H1: partial response rate for miconazole Lauriad minus partial response rate for Mycelex troches is greater than -0.15</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority assumptions:
Type of test: one-sided Inferiority margin: -15% Type I error: 2.5% Type II error: 5%</non_inferiority_desc>
            <p_value>0.9033</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>compare proportion of partial response</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mycological Cure at the Test of Cure Visit (Day 17-22)</title>
        <description>Mycological cure was defined as a patient who had &quot;no yeast isolated&quot; when oral specimens were cultured for fungi.</description>
        <time_frame>17 to 22 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Mycological Cure at the Test of Cure Visit (Day 17-22)</title>
          <description>Mycological cure was defined as a patient who had &quot;no yeast isolated&quot; when oral specimens were cultured for fungi.</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mycological Cure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycological Failure-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycological Cure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycological Failure-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority statistical analysis for ITT population.</non_inferiority_desc>
            <p_value>0.5816</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>difference in proportion mycologic cure</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority statistical analysis for PP population</non_inferiority_desc>
            <p_value>0.4439</p_value>
            <p_value_desc>Significance level was &lt;0.025.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>difference in proportion mycologic cure</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse at the Late Post-Therapy Visit (Day 35-38)</title>
        <description>&quot;Number of patients&quot; represents the number of participants who completed visit 6 (the late post-therapy visit on Days 35-38) and had been a clinical success at test-of-cure visit (visit 5). For this subset of participants, relapse was defined as a patient who responded to treatment by clinical cure or improvement (i.e., &quot;clinical success&quot;) on Days 17-22 at the test-of-cure visit (visit 5) and subsequently had an increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit on Days 35-38 (visit 6). No relapse indicates participants who were considered a &quot;clinical success&quot; at visit 5 and did not have a subsequent increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit (visit 6). The remaining number of participants in the Intent-to-Treat population who did not meet the criteria for relapse assessment at visit 6 is listed under &quot;Not Analyzed-ITT&quot;.</description>
        <time_frame>35 to 38 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse at the Late Post-Therapy Visit (Day 35-38)</title>
          <description>&quot;Number of patients&quot; represents the number of participants who completed visit 6 (the late post-therapy visit on Days 35-38) and had been a clinical success at test-of-cure visit (visit 5). For this subset of participants, relapse was defined as a patient who responded to treatment by clinical cure or improvement (i.e., &quot;clinical success&quot;) on Days 17-22 at the test-of-cure visit (visit 5) and subsequently had an increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit on Days 35-38 (visit 6). No relapse indicates participants who were considered a &quot;clinical success&quot; at visit 5 and did not have a subsequent increase in the extent of oral lesions or symptoms, as assessed at the late post-therapy visit (visit 6). The remaining number of participants in the Intent-to-Treat population who did not meet the criteria for relapse assessment at visit 6 is listed under &quot;Not Analyzed-ITT&quot;.</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)
PP (all patients in ITT without major protocol deviation, with positive fungal culture, completed at least 10 days of treatment, had main efficacy criteria at test of cure, compliant within 71.4% to 120%, and no forbidden medications taken)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of patients-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No relapse-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Analyzed-ITT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of patients-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relapse-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No relapse-PP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority statistical analysis for ITT population.</non_inferiority_desc>
            <p_value>0.8330</p_value>
            <p_value_desc>Significance level is &lt;0.025.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>difference in proportion relapsed</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority statistical analysis for PP population.</non_inferiority_desc>
            <p_value>0.9738</p_value>
            <p_value_desc>Significance level is &lt;0.025.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>difference in proportion relapsed</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oral Discomfort Using Visual Analog Scale (VAS)</title>
        <description>Visual analog scale was used by the patient in the patient diary. The scale ranged from 0 (no oral discomfort) to 10 (maximum oral discomfort)</description>
        <time_frame>14 days</time_frame>
        <population>Intent-to-Treat (ITT, all randomized patients who took at least 1 dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Discomfort Using Visual Analog Scale (VAS)</title>
          <description>Visual analog scale was used by the patient in the patient diary. The scale ranged from 0 (no oral discomfort) to 10 (maximum oral discomfort)</description>
          <population>Intent-to-Treat (ITT, all randomized patients who took at least 1 dose of study medication)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General and Local Tolerability and Oral Discomfort</title>
        <description>Overall local adverse reactions, including gingival inflammation, gum pain, alterations in taste of food when eating, alterations in taste when not eating, and dry mouth. Visit 4 occurred on Day 14.</description>
        <time_frame>14 days</time_frame>
        <population>Safety Population (same as ITT population, includes all randomized patients who took at least one dose of the study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>General and Local Tolerability and Oral Discomfort</title>
          <description>Overall local adverse reactions, including gingival inflammation, gum pain, alterations in taste of food when eating, alterations in taste when not eating, and dry mouth. Visit 4 occurred on Day 14.</description>
          <population>Safety Population (same as ITT population, includes all randomized patients who took at least one dose of the study medication)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gingival Inflammation-Visit 4 (R canine fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Gingival Inflammation-Visit 4 (R canine fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235"/>
                    <measurement group_id="O2" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Inflammation)-Visit 4 (R fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gingival Inflammation-Visit 4 (L canine fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Gingival Inflammation-Visit 4 (L canine fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Inflammation)-Visit 4 (L fossa)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gum Pain-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Gum Pain-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                    <measurement group_id="O2" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Gum Pain)-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste of Food Alteration-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Taste of Food Alteration-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Taste of Food Alteration)-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taste When Not Eating Alteration-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Taste When Not Eating Alteration-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Taste When Not Eating)-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dry Mouth-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Dry Mouth-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data Missing (Dry Mouth)-Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Adhesion of Miconazole Lauriad 50 mg Mucoadhesive Buccal Tablet</title>
        <description>The mean durations of adhesion from initiation of treatment to Day 14 of miconazole Lauriad 50 mg mucoadhesive buccal tablet (or, in the case of the Clotrimazole troches treatment arm, the placebo mucoadhesive buccal tablet) were rounded to the nearest hour</description>
        <time_frame>14 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Adhesion of Miconazole Lauriad 50 mg Mucoadhesive Buccal Tablet</title>
          <description>The mean durations of adhesion from initiation of treatment to Day 14 of miconazole Lauriad 50 mg mucoadhesive buccal tablet (or, in the case of the Clotrimazole troches treatment arm, the placebo mucoadhesive buccal tablet) were rounded to the nearest hour</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Exposure of Miconazole Lauriad 50 mg Bioadhesive Buccal Tablet</title>
        <description>Number of patients with detectable plasma concentration at Visit 3 (day 7)</description>
        <time_frame>7 days</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Exposure of Miconazole Lauriad 50 mg Bioadhesive Buccal Tablet</title>
          <description>Number of patients with detectable plasma concentration at Visit 3 (day 7)</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Susceptibility of Candida Species by Microdilution Test</title>
        <description>minimum inhibitory concentration (MIC) in nonresponders at test-of-cure visit</description>
        <time_frame>Initiation of treatment to Day 17 to 22</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication), nonresponders (participants with progression to a higher visible lesion extent score or no reduction in oral lesion extent score at the test of cure [Day 17 to 22] visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Susceptibility of Candida Species by Microdilution Test</title>
          <description>minimum inhibitory concentration (MIC) in nonresponders at test-of-cure visit</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication), nonresponders (participants with progression to a higher visible lesion extent score or no reduction in oral lesion extent score at the test of cure [Day 17 to 22] visit)</population>
          <units>mcg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clotrimazole MIC for C. albicans (n=9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0099" spread="0.0040"/>
                    <measurement group_id="O2" value="0.0073" spread="0.0039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Miconazole MIC for C. albicans (n=9, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0764" spread="0.0995"/>
                    <measurement group_id="O2" value="0.1664" spread="0.3679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Clotrimazole minimum inhibitory concentration (MIC) between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1860</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis for Miconazole minimum inhibitory concentration (MIC) between treatment groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9564</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Compliance</title>
        <description>Number of patients who were 100% compliant with the treatment regimen</description>
        <time_frame>Initiation of treatment to Day 14</time_frame>
        <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Miconazole Lauriad Buccal Tablet</title>
            <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Clotrimazole Troches</title>
            <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Compliance</title>
          <description>Number of patients who were 100% compliant with the treatment regimen</description>
          <population>ITT (all randomized patients who took at least 1 dose of study medication)</population>
          <units>participants compliant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days study treatment, then 21 days of follow-up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Miconazole Lauriad Buccal Tablet</title>
          <description>Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Clotrimazole Troches</title>
          <description>Clotrimazole troches, 10 mg, 5 times per day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>AIDS dementia complex</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Retroviral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="290"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="290"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="290"/>
                <counts group_id="E2" events="28" subjects_affected="23" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="290"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="290"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="290"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="290"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="290"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="290"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="290"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="290"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="290"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="290"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pierre Attali</name_or_title>
      <organization>Bioalliance Pharma</organization>
      <phone>+33 (0)1 45 58 76 00</phone>
      <email>pierre.attali@bioalliancepharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

